This news release focuses on a study on the gut microbiome, an emerging avenue of research. The release would have been better had it provided more detail about the study (including the number of patients involved) and the sizes of the beneficial effects. Instead, the release relies heavily on speculative language, suggesting a direct connection between gut inflammation or “microbial imbalances” and mood disorders. Despite a slew of recent studies, no causal relationship has been established between the microbiome and mental health.
The microbiome, a compelling area of research, is sometimes presented in news releases and news stories as a new panacea for a wide range of health conditions. But what’s currently unknown in this area significantly outweighs what is known.
Writing about this new field of research requires an emphasis on caveats. News releases should avoid implying causality (ie. “good bacteria” or “a balanced microbiome” is responsible for good outcomes), and highlight study limitations.
As of 2018, and contrary to what this new release headline implies, probiotics have not been shown to help millions of patients suffering from any disease.
Neither the cost, composition, or dosing of the intervention — a probiotic preparation of strains of a Lactobacillus and Bifidobacterium — is provided.
The release notes that the 6-month study yielded the following results:
The group randomized to receive the probiotic, on average, “didn’t return to hospital as quickly … required less in-patient treatment time … [and the] beneficial effects were most pronounced in those patients who exhibited abnormally high levels of inflammation” when compared to the placebo group.
However no data is provided to support these outcomes. The news release should have included information about the number of patients in the trial, the schedule of probiotic dosing given to the participants, the changes in inflammation levels, the difference in number of rehospitalizations, and other details.
The release also includes some other unsubstantiated claims, such as:
The release doesn’t mention any potential harms of probiotics nor the fact that they are not regulated for safety and effectiveness.
The release doesn’t describe the study parameters. According to the abstract, it was a double-blind randomized comparison of 33 people on probiotics after discharge for a manic episode, and 33 patients who took placebo.
The study had some limitations that should have been mentioned in the release. First, the drop-out was high with only 79% (n=52) of the original group completing the 6-month follow-up.
Second, all the subjects continued to take their usual medications and these were not standardized. Therefore, some of the differences noted could be attributed to medications, not the intervention.
Finally, no conclusions regarding the role of “inflammation” in modulating behavior can be drawn since inflammatory measurements were not taken in the gut or the cerebrospinal fluid.
The release doesn’t engage in disease mongering. It provides context on the prevalence of bipolar disorder in the US.
Funding is not mentioned.
A version of the study published in April 2018 noted that the lead author had no conflicts of interest to disclose.
The news release mentions the standard treatments for bipolar disorder:
“Currently, the standard treatment (of bipolar illness) includes a combination of psychotherapy and prescription medications such as mood stabilizers and antipsychotics.”
The dosage and composition of the probiotic mixture used in this study are not clarified. Therefore, readers have no idea if just any probiotic will do. This is worrisome since some readers — particularly those with bipolar illness — may extrapolate from the news release headline and start self-medicating based on these preliminary findings that don’t prove probiotics help bipolar illness.
While the use of probiotics to treat bipolar disorder is part of an “an emerging field of research” and therefore novel, it hasn’t been established through this or other research as an effective intervention.
The release implies that the study builds on previous research in this area. In that case, it would have been helpful for the news release to disclose those aspects of the study had been previously published.
Along with the unsubstantiated headline suggesting “millions” of people who suffer with bipolar disease could be helped by probiotics, the release employs the pseudoscientific term “gut-brain axis” to suggest there are known connections between good and bad bacteria, microbial balance, and psychiatric mood disorders.
But without data, much of the language used throughout the news release is unjustified.
This news release focuses on a study of the gut microbiome, an emerging avenue of research. The release would have been better had it provided more detail about the study (including the number of patients involved) and the sizes of the beneficial effects. Instead, the release relies heavily on speculative language, suggesting a direct connection between gut inflammation or “microbial imbalances” and mood disorders. Despite a slew of recent studies, no causal relationship has been established between the microbiome and mental health.
The microbiome, a compelling area of research, is sometimes presented in news releases and news stories as a new panacea for a wide range of health conditions. But what’s currently unknown in this area significantly outweighs what is known.
Writing about this new field of research requires an emphasis on caveats. News releases should avoid implying causality (ie. “good bacteria” or “a balanced microbiome” is responsible for good outcomes), and highlight study limitations.
As of 2018, and contrary to what this new release headline implies, probiotics have not been shown to help millions of patients suffering from any disease.
Neither the cost, composition, or dosing of the intervention — a probiotic preparation of strains of a Lactobacillus and Bifidobacterium — is provided.
The release notes that the 6-month study yielded the following results:
The group randomized to receive the probiotic, on average, “didn’t return to hospital as quickly … required less in-patient treatment time … [and the] beneficial effects were most pronounced in those patients who exhibited abnormally high levels of inflammation” when compared to the placebo group.
However no data are provided to support these outcomes. The news release should have included information about the number of patients in the trial, the schedule of probiotic dosing given to the participants, the changes in inflammation levels, the difference in number of rehospitalizations, and other details.
The release also includes some other unsubstantiated claims, such as:
The release doesn’t mention any potential harms of probiotics nor the fact that they are not regulated for safety and effectiveness.
The release doesn’t describe the study parameters. According to the abstract, it was a double-blind randomized comparison of 33 people on probiotics after discharge for a manic episode, and 33 patients who took placebo.
The study had some limitations that should have been mentioned in the release. First, the drop-out was high with only 79% (n=52) of the original group completing the 6-month follow-up.
Second, all the subjects continued to take their usual medications and these were not standardized. Therefore, some of the differences noted could be attributed to medications, not the intervention.
Finally, no conclusions regarding the role of “inflammation” in modulating behavior can be drawn since inflammatory measurements were not taken in the gut or the cerebrospinal fluid.
The release doesn’t engage in disease mongering. It provides context on the prevalence of bipolar disorder in the US.
Funding is not mentioned.
A version of the study published in April 2018 noted that the lead author had no conflicts of interest to disclose.
The news release mentions the standard treatments for bipolar disorder:
“Currently, the standard treatment (of bipolar illness) includes a combination of psychotherapy and prescription medications such as mood stabilizers and antipsychotics.”
The dosage and composition of the probiotic mixture used in this study are not clarified. Therefore, readers have no idea if just any probiotic will do. This is worrisome since some readers — particularly those with bipolar illness — may extrapolate from the news release headline and start self-medicating based on these preliminary findings that don’t prove probiotics help bipolar illness.
While the use of probiotics to treat bipolar disorder is part of an “an emerging field of research” and therefore novel, it hasn’t been established through this or other research as an effective intervention.
The release implies that the study builds on previous research in this area. In that case, it would have been helpful for the news release to disclose those aspects of the study had been previously published.
Along with the unsubstantiated headline suggesting “millions” of people who suffer with bipolar disease could be helped by probiotics, the release employs the pseudoscientific term “gut-brain axis” to suggest there are known connections between good and bad bacteria, microbial balance, and psychiatric mood disorders.
But without data, much of the language used throughout the news release is unjustified.
Systematic, Criteria-Driven
For breakfast, @GarySchwitzer swallows 2 observational studies with an anti-irritant chaser. https://www.healthnewsreview.org/2020/06/for-breakfast-give-me-2-observational-studies-and-an-anti-irritant/#.XvtqMk8i5e8.twitter
Sitting & cancer...alcohol & improved cognition. Waking up to a double whammy of miscommunicated observational studies.
https://www.healthnewsreview.org/2020/06/for-breakfast-give-me-2-observational-studies-and-an-anti-irritant/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like